Leukaemia Trial, Recruiting NCT05237986 Sponsor: National Cancer Institute (NCI) Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT05237986
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients with leukemia or lymphoma:

  • People who have been diagnosed with leukemia or lymphoma that has come back or has not responded to previous treatment, and who are scheduled to receive a type of treatment called CAR T-cell therapy at one of the participating hospitals
  • The CAR T-cell treatment program the person is enrolled in must allow their data to be shared for this study
  • People aged 5 to 35 years old
  • People who have a caregiver (such as a parent or close family member) who is willing to complete assessments about them as part of the study
  • People under 18, or older if needed, must have a caregiver who can help set up a suitable environment for remote (online) assessments
  • People who can speak and understand English or Spanish
  • People who have access to a computer or tablet with a camera and an internet connection
  • The person themselves, or their parent or legal guardian, must be willing and able to sign a written consent form

For caregivers taking part:

  • People aged 18 or older who are a caregiver for a patient meeting the criteria above
  • People who can speak and read English or Spanish
  • People who have access to a computer or tablet
  • Caregivers of children under 18 (or older if needed) must be willing to help set up a suitable environment for remote assessments
  • People who are willing and able to sign a written consent form

Who may not be able to join:

  • Patients who have a pre-existing intellectual disability that affects all areas of thinking and learning (for example, Down Syndrome)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pamela L Wolters, Ph.D., National Cancer Institute (NCI)

Phone: (240) 760-6970

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 June 2025
Est. completion
1 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To evaluate changes in working memory in children and young adults with relapsed/refractory leukemia or lymphoma at 12 months post CAR T-cell therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov